Coya Therapeutics logo

Coya TherapeuticsNASDAQ: COYA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 December 2022

Next earnings report:

19 March 2025

Last dividends:

N/A

Next dividends:

N/A
$100.75 M
-39%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-70%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$6.03+$0.07(+1.17%)

Dividend

No data over the past 3 years
$133.33 K$100.00 K

Analysts recommendations

Institutional Ownership

COYA Latest News

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
benzinga.com29 October 2024 Sentiment: NEGATIVE

On Tuesday, Coya Therapeutics, Inc. COYA released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)
businesswire.com29 October 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease were announced today at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The study was led by Dr. Alireza Faridar an.

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
seekingalpha.com13 October 2024 Sentiment: POSITIVE

Coya Therapeutics is developing treatments for neurodegenerative diseases, with its lead drug COYA 302 showing promising early results in ALS trials. Despite recent delays, the adverse investor reaction presents an investment opportunity as the company progresses on its pipeline development. The partnership with Dr. Reddy's Labs validates COYA 302 and provides a mechanism for rapid commercial scaling upon FDA approval.

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid
businesswire.com02 August 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announces that data from the IIT, a double-blind, placebo-controlled, phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer's Association w.

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
businesswire.com20 June 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives. The development and production of exosomes from patients' regulatory T cells will be funded by the Johnson.

Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment
youtube.com23 May 2024 Sentiment: POSITIVE

Coya Therapeutics (COYA) is a clinical-stage company focused on developing multi-modality Treg therapies. CEO Howard Berman joins Nicole Petallides to give an overview of the company.

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease
businesswire.com22 May 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the completion of a randomized, double-blind, placebo-controlled Phase 2 study of LD IL-2 in patients with mild-to-moderate AD. The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheim.

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
businesswire.com20 May 2024 Sentiment: POSITIVE

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the Alzheimer's Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company's common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million. The ADDF's mission is to rapidly accelerate the development of drugs to prevent, trea.

Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
Business Wire25 August 2023 Sentiment: NEUTRAL

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Deve.

Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics
Seeking Alpha14 August 2023 Sentiment: POSITIVE

Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could potentially be the best drug on the market, halting ALS disease progression. Coya's shares appear undervalued based on simplified valuation methods (risk-adjusted, discounted peak sales multiple).

What type of business is Coya Therapeutics?

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

What sector is Coya Therapeutics in?

Coya Therapeutics is in the Healthcare sector

What industry is Coya Therapeutics in?

Coya Therapeutics is in the Biotechnology industry

What country is Coya Therapeutics from?

Coya Therapeutics is headquartered in United States

When did Coya Therapeutics go public?

Coya Therapeutics initial public offering (IPO) was on 29 December 2022

What is Coya Therapeutics website?

https://www.coyatherapeutics.com

Is Coya Therapeutics in the S&P 500?

No, Coya Therapeutics is not included in the S&P 500 index

Is Coya Therapeutics in the NASDAQ 100?

No, Coya Therapeutics is not included in the NASDAQ 100 index

Is Coya Therapeutics in the Dow Jones?

No, Coya Therapeutics is not included in the Dow Jones index

When was Coya Therapeutics the previous earnings report?

No data

When does Coya Therapeutics earnings report?

The next expected earnings date for Coya Therapeutics is 19 March 2025